Loading exclusive…
$KPTI: Research Costs Blew the Quarter. The Filing Still Stands
The miss is a development bill, not a franchise break. Cash runway and the filing clock are what the tape should price, not the EPS print.
Key Points
- Q2 EPS of ($2.32) missed consensus of ($1.53) by 63% due to higher R&D spend.
- Revenue beat estimates, showing commercial stability.
- Company confirmed continued progress toward myelofibrosis sNDA submission.
- Cash runway remains sufficient for near-term regulatory milestones.
- Market reaction muted; focus remains on binary regulatory catalyst.
What To Watch
- Official sNDA submission date and FDA acknowledgment.
- Next quarter’s cash burn rate and balance sheet updates.
- Any regulatory feedback or questions from the FDA post-submission.
- Potential partnership announcements to bolster cash reserves.